Publication | Open Access
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
1K
Citations
34
References
2019
Year
Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1